N@N

Syneron Prevails in Patent Litigation Case With Cardiofocus

^{Published on 2010-05-06 06:11:14 - Market Wire}
 

YOKNEAM, ISRAEL--(Marketwire - May 6, 2010) - Syneron Medical Ltd. (NASDAQ: [ ELOS ]), the leading global aesthetic device company, today announced the successful resolution of patent litigation against its subsidiary, Candela Corporation, by Cardiofocus, Inc.

On April 30, 2010, the United States District Court for the District of Massachusetts approved dismissal with prejudice of all claims made by Cardiofocus against Candela in a lawsuit pending against Candela and other companies.

On February 19, 2008, Cardiofocus filed suit against Candela asserting infringement of three U.S. patents by Candela's Smoothbeam^®. Shortly after the filing, Candela filed petitions with the U.S. Patent and Trademark Office ("USPTO") to reexamine the patents. The USPTO granted the petitions, and, on October 14, 2008, the District Court stayed the litigation pending the USPTO's reexaminations. As a result of the reexamination process, the scope of the claims was substantially narrowed and the USPTO rejected most of the claims asserted by Cardiofocus against Candela. Cardiofocus agreed to dismiss all claims against Candela in the lawsuit.

Louis P. Scafuri, Chief Executive Officer, commented, "This litigation dismissal reinforces Candela's IP portfolio and commitment to defending its validity. This is a vital component of Candela's operations and we believe it will continue to underscore the strength of our global presence. The decision is an important step in our strategic initiative to expand the size and depth of our product offering and to be the leader in the global aesthetic device space."

About Syneron Medical Ltd.

Syneron Medical Ltd. (NASDAQ: [ ELOS ]) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.

Additional information can be found at [ www.syneron.com ].